ADC Therapeutics SA (ADCT) vs Anika Therapeutics (ANIK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Anika Therapeutics (ANIK) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 114.9% versus a loss of 67.1%. Over five years, ANIK leads with a -53.1% price change compared with -94.4% for ADCT. Anika Therapeutics is the larger company by market cap ($257.4 million vs $203.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | ANIK |
|---|---|---|
| Share price | $1.59 | $19.23 |
| Market cap | $202.99M | $257.35M |
| 1-day change | +11.97% | -1.54% |
| YTD return | -59.77% | +103.23% |
| 1-year return | -67.05% | +114.85% |
| 5-year return | -94.42% | -53.12% |
| Forward P/E | — | 20.24 |
| EPS (TTM) | $-0.60 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $22.88 |
| 52-week low | $0.78 | $8.67 |
| Distance from 52-week high | -68.07% | -15.95% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +109.43% | +19.60% |
| Average volume | 1.35M | 98.57K |
| Shares outstanding | 127.67M | 13.38M |
| Employees | 188 | 235 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIK has outperformed ADCT by 181.9 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Anika Therapeutics
ANIK stock →Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
Health Care · Medical/Dental Instruments · 235 employees
ADCT vs ANIK FAQ
Which is bigger, ADC Therapeutics SA or Anika Therapeutics?
Anika Therapeutics (ANIK) is larger, with a market capitalization of $257.35M compared with $202.99M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or ANIK?
ANIK returned +114.85% over the past 12 months, compared with -67.05% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Anika Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ADC Therapeutics SA and Medical/Dental Instruments for Anika Therapeutics.